OR2A7/OR2A4 Antibody

What are OR2A7 and OR2A4, and why are they scientifically significant?

OR2A7 and OR2A4 are olfactory receptors belonging to the G protein-coupled receptor (GPCR) family, traditionally known for detecting odor molecules in the nasal epithelium and playing a key role in the sense of smell. Their scientific significance has expanded considerably with the discovery of their extranasal expression in tissues such as melanocytes and skin, as well as their aberrant expression in certain cancers . These findings suggest broader physiological roles beyond olfaction, including potential involvement in cellular growth regulation, differentiation, and pathological processes. OR2A7 and OR2A4 have particularly gained attention in melanocyte research and cancer diagnostics, making them important targets for scientific investigation .

What applications is the OR2A7/OR2A4 antibody validated for?

The OR2A7/OR2A4 Polyclonal Antibody (PACO01218) has been validated for multiple experimental applications. These include:

• Western Blotting (WB): Recommended dilution range of 1:500-1:2000

• Immunofluorescence (IF): Recommended dilution range of 1:200-1:1000

• Enzyme-Linked Immunosorbent Assay (ELISA)

The antibody demonstrates high specificity and sensitivity for human samples, making it particularly valuable for investigating these receptors in human tissues and cell lines . Researchers should conduct preliminary dilution tests when applying this antibody to new experimental systems to determine optimal working concentrations.

What are the optimal storage and handling conditions for OR2A7/OR2A4 antibody?

For maximum stability and performance, the OR2A7/OR2A4 antibody should be stored according to these specifications:

• Physical form: Liquid

• Storage buffer: PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• Recommended storage temperature: -20°C (avoid repeated freeze-thaw cycles)

• Aliquoting is recommended for antibodies that will be used multiple times to minimize freeze-thaw cycles

• Working dilutions should be prepared fresh before use and stored at 4°C for short-term applications (1-2 days)

Proper storage and handling are crucial for maintaining antibody integrity and experimental reproducibility. Researchers should document lot numbers and validate new lots against previous experimental results.

How can I validate OR2A7/OR2A4 antibody specificity in my experimental system?

Validating antibody specificity is a critical step for ensuring reliable research outcomes. For OR2A7/OR2A4 antibody, consider these methodological approaches:

• Positive and negative controls:

  • Use tissues or cell lines with known OR2A7/OR2A4 expression (e.g., nasal epithelium, melanocytes) as positive controls

  • Include tissues or cell lines known to lack these receptors as negative controls

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide (derived from the C-terminal region of human OR2A4/7) before application

  • Signal disappearance indicates specificity for the target epitope

• siRNA knockdown:

  • Reduce OR2A7/OR2A4 expression in cells using targeted siRNA

  • Compare antibody signal in knockdown versus control cells

• Recombinant protein testing:

  • Test the antibody against recombinant OR2A7 and OR2A4 proteins

  • Evaluate cross-reactivity with closely related olfactory receptors

Document all validation steps thoroughly to support the reliability of subsequent experimental findings.

How can I design experiments to investigate extranasal OR2A4/7 function in melanocytes?

When investigating extranasal OR2A4/7 function in melanocytes, a comprehensive experimental design should include:

• Expression profiling:

  • Confirm OR2A4/7 expression at both transcript (RT-qPCR) and protein levels (Western blot, immunofluorescence) in your melanocyte model

  • Compare expression between primary melanocytes and melanocyte cell lines

• Functional stimulation assays:

  • Treat melanocytes with the known OR2A4/7 agonist cyclohexyl salicylate (CHS) at varying concentrations (typically 100-500 μM)

  • Include appropriate vehicle controls

• Downstream signaling analysis:

  • Measure intracellular cAMP levels using ELISA or FRET-based biosensors

  • Monitor calcium influx using calcium-sensitive dyes or genetically encoded calcium indicators

  • Assess MAPK pathway activation through phosphorylation of p38 and p42/44 (ERK1/2) using phospho-specific antibodies

• Functional readouts:

  • Quantify melanin production using spectrophotometric methods (absorbance at 405 nm)

  • Assess cell proliferation using BrdU incorporation or Ki-67 staining

  • Evaluate cell differentiation by monitoring expression of melanocyte differentiation markers (e.g., MITF, TYR, TYRP1)

This experimental framework allows for a comprehensive characterization of how OR2A4/7 signaling impacts melanocyte biology, focusing on the established connection between receptor activation and melanogenesis regulation.

What approaches should be used to study the potential role of OR2A4/7 in cancer diagnosis and prognosis?

Based on recent findings regarding OR2A4/7 expression in clear cell renal cell carcinoma (KIRC), researchers can explore its diagnostic and prognostic potential using these methodological approaches:

• Expression analysis:

  • Compare OR2A4/7 expression in tumor vs. normal tissues using qRT-PCR, Western blotting, and immunohistochemistry

  • Analyze expression data from public cancer databases (e.g., TCGA) to identify correlations with clinical parameters

  • Consider combining analysis with other olfactory receptors (e.g., OR51E1, OR7E14P) for improved diagnostic power

• Diagnostic marker validation:

  • Perform ROC curve analysis to assess sensitivity and specificity

  • Calculate Area Under Curve (AUC) values (OR2A4 has shown an AUC of 0.951 in KIRC)

  • Test multi-marker panels (OR2A4 + OR51E1 + OR7E14P has shown improved diagnostic performance with AUC of 0.972)

• Prognostic significance assessment:

  • Stratify patients into high and low expression groups based on median expression levels

  • Perform Kaplan-Meier survival analysis to correlate expression with patient outcomes

  • Conduct multivariate Cox regression analysis to control for confounding factors

• Sex-specific analysis:

  • Separate analysis for male and female subjects due to observed sex-based differences in OR2A7 expression

  • Investigate hormonal influences on receptor expression

This comprehensive approach enables thorough evaluation of OR2A4/7 as both diagnostic and prognostic biomarkers in cancer research, with particular relevance to renal cell carcinoma.

How do I troubleshoot weak or nonspecific signals when using OR2A7/OR2A4 antibody in Western blotting?

When encountering weak or nonspecific signals with OR2A7/OR2A4 antibody in Western blotting, implement this systematic troubleshooting approach:

• Sample preparation optimization:

  • Ensure complete protein extraction using appropriate lysis buffers containing protease inhibitors

  • Consider membrane-enriched fractions for better detection of these transmembrane GPCRs

  • Avoid excessive sample heating which may cause aggregation of membrane proteins

• Antibody dilution optimization:

  • Test a range of dilutions around the recommended 1:500-1:2000 range

  • Extend primary antibody incubation time (overnight at 4°C) for weak signals

  • Consider signal amplification systems for low-abundance targets

• Blocking and washing protocol refinement:

  • Test alternative blocking agents (5% BSA often performs better than milk for phospho-specific epitopes)

  • Increase washing stringency (higher detergent concentration or additional washes) for high background

  • Reduce washing intensity if signal is too weak

• Membrane transfer parameters:

  • Optimize transfer conditions for these membrane proteins (typically 30-40 kDa)

  • Consider semi-dry transfer for smaller proteins or wet transfer for larger proteins

  • Verify transfer efficiency using reversible staining methods (Ponceau S)

• Target validation:

  • Confirm expected molecular weight (approximately 35-36 kDa for OR2A7/OR2A4)

  • Be aware that post-translational modifications may alter migration patterns

  • Use positive controls with known OR2A7/OR2A4 expression

This methodical approach helps identify the specific factors causing suboptimal Western blot results and provides targeted solutions for improvement.

What strategies can address cross-reactivity concerns between OR2A7 and OR2A4 in experimental systems?

Given the high sequence similarity between OR2A7 and OR2A4, cross-reactivity is a significant concern. Researchers can implement these strategies to address this issue:

• Epitope mapping and antibody selection:

  • Review the immunizing peptide sequence used for the OR2A7/OR2A4 antibody (derived from the C-terminal region)

  • Select antibodies raised against regions with maximum sequence divergence between the two receptors

  • Consider custom antibody development if commercially available options cannot distinguish between the receptors

• Genetic manipulation approaches:

  • Employ receptor-specific siRNA knockdown to confirm antibody specificity

  • Use CRISPR-Cas9 to selectively knockout either OR2A7 or OR2A4

  • Create overexpression systems with epitope-tagged versions of each receptor

• Transcript-level verification:

  • Design PCR primers at divergent regions to distinguish between OR2A7 and OR2A4 mRNAs

  • Confirm expression patterns using receptor-specific probes

  • Utilize RNA-seq data to quantify expression of individual receptors

• Functional discrimination:

  • Identify ligands with differential selectivity for OR2A7 versus OR2A4

  • Compare signaling outcomes and downstream effects

  • Document activation profiles using reporter assays

These approaches enable researchers to delineate the specific contributions of each receptor in systems where both OR2A7 and OR2A4 may be present, enhancing experimental precision and data interpretation.

How should researchers interpret contradictory findings about OR2A4/7 expression patterns across different tissues?

When facing contradictory reports about OR2A4/7 expression patterns, researchers should implement this methodological framework:

• Technical factors assessment:

  • Compare detection methods used across studies (RNA-seq, qRT-PCR, Western blot, immunohistochemistry)

  • Evaluate antibody specificity and validation methods in each study

  • Consider sensitivity thresholds of different detection techniques

• Biological variables consideration:

  • Analyze sample characteristics including donor demographics (age, sex, ethnicity)

  • Note pathological status of tissues (normal vs. disease states)

  • Assess potential environmental or experimental factors influencing expression

• Transcript vs. protein correlation:

  • Compare transcript and protein data within the same study when available

  • Be aware that post-transcriptional regulation may lead to discrepancies

  • Consider protein half-life and stability factors

• Context-dependent expression:

  • Recognize that olfactory receptor expression can be dynamic and context-dependent

  • Document the observed sex-based differences in OR2A7 expression reported in KIRC studies

  • Consider potential regulatory mechanisms including epigenetic factors

This analytical approach enables researchers to reconcile apparently contradictory findings by identifying methodological differences, biological variables, and regulatory mechanisms that may explain diverse expression patterns reported in the literature.

What statistical approaches are most appropriate for analyzing OR2A4/7 expression data in cancer studies?

When analyzing OR2A4/7 expression data in cancer research, appropriate statistical methodologies are essential:

• Differential expression analysis:

  • For normally distributed data: Student's t-test for two-group comparisons

  • For non-normally distributed data: Wilcoxon rank-sum test (Mann-Whitney U test)

  • For multi-group comparisons: ANOVA with appropriate post-hoc tests (normal distribution) or Kruskal-Wallis (non-parametric)

• Diagnostic potential evaluation:

  • ROC curve analysis to determine sensitivity and specificity

  • Calculate and report Area Under Curve (AUC) values with confidence intervals

  • Consider combinatorial marker approaches (e.g., combined OR2A4, OR51E1, and OR7E14P improves AUC to 0.972)

• Survival analysis:

  • Kaplan-Meier curves stratified by expression levels (typically high vs. low based on median)

  • Log-rank test to assess statistical significance of survival differences

  • Cox proportional hazards regression for multivariate analysis incorporating clinical covariates

• Sample size considerations:

  • Conduct power analysis to determine adequate sample sizes

  • Report confidence intervals alongside p-values

  • Apply multiple testing corrections (e.g., Benjamini-Hochberg) when analyzing multiple genes

• Sex-stratified analysis:

  • Separate analysis for male and female subjects due to documented sex-based differences

  • Interaction term analysis in regression models to quantify sex-specific effects

This comprehensive statistical framework ensures robust analysis of OR2A4/7 expression data in cancer studies, accounting for the complexity of biological systems and the need for appropriate biomarker validation protocols.

How can researchers design experiments to elucidate the signaling pathways downstream of OR2A4/7 activation?

To comprehensively map the signaling pathways downstream of OR2A4/7 activation, researchers should implement this experimental design:

• Receptor activation and validation:

  • Stimulate cells expressing OR2A4/7 with cyclohexyl salicylate (CHS) or other validated agonists

  • Include appropriate vehicle controls and concentration gradients

  • Confirm receptor activation using cAMP assays (OR2A4/7 couples to Gαs proteins)

• Temporal signaling analysis:

  • Perform time-course experiments (typical points: 0, 5, 15, 30, 60 minutes, 3, 6, 24 hours)

  • Document early signaling events (cAMP elevation, Ca²⁺ flux) and later transcriptional responses

  • Use phospho-specific antibodies to track kinase activation (p38, ERK1/2) at different time points

• Pathway delineation:

  • Apply specific pathway inhibitors:

    • PKA inhibitors (e.g., H-89) to block cAMP-dependent signaling

    • MAPK inhibitors (e.g., SB203580 for p38, U0126 for ERK1/2)

    • Calcium chelators (e.g., BAPTA-AM) to block calcium-dependent signaling

  • Assess the impact of each inhibitor on downstream biological responses

• Integration with physiological responses:

  • In melanocytes: measure melanin production, proliferation, and differentiation markers

  • In cancer cells: assess proliferation, migration, invasion, and apoptosis

  • Use pathway inhibitors to establish causal relationships between specific signaling events and functional outcomes

This experimental framework allows researchers to construct detailed signaling maps connecting OR2A4/7 activation to biological responses, potentially revealing novel therapeutic targets and mechanisms of action.

How can the OR2A7/OR2A4 antibody be used to investigate potential roles in cancer pathophysiology?

The OR2A7/OR2A4 antibody can be strategically employed to investigate cancer pathophysiology through these methodological approaches:

• Expression profiling across cancer types:

  • Perform immunohistochemistry (IHC) on tissue microarrays spanning multiple cancer types

  • Compare expression in matched tumor/normal pairs using Western blot and IHC

  • Correlate expression with histopathological features and clinical parameters

• Cellular localization studies:

  • Use immunofluorescence to determine subcellular localization in cancer cells

  • Compare localization patterns between normal and malignant cells

  • Investigate potential redistribution during disease progression

• Functional studies in cancer models:

  • Employ the antibody for immunoprecipitation to identify interacting partners in cancer cells

  • Develop blocking antibody approaches to inhibit receptor function

  • Use antibody-based detection to monitor changes in expression following therapeutic interventions

• Biomarker validation:

  • Develop standardized IHC protocols for potential diagnostic applications

  • Correlate expression with clinical outcomes in patient cohorts

  • Evaluate potential as a companion diagnostic for targeted therapies

• Mechanistic investigations:

  • Combine with phospho-specific antibodies to monitor downstream signaling

  • Track expression changes during epithelial-mesenchymal transition

  • Investigate correlation with cancer stem cell markers

These approaches leverage the specificity of the OR2A7/OR2A4 antibody to advance understanding of these receptors in cancer biology, potentially revealing novel diagnostic approaches and therapeutic targets.

What experimental design considerations are critical when investigating OR2A4/7 in melanocyte regulation?

When investigating OR2A4/7 in melanocyte regulation, these experimental design considerations are essential:

• Cell model selection:

  • Primary human melanocytes: Closest to physiological condition but limited lifespan

  • Immortalized melanocyte lines: More experimental flexibility but may have altered signaling

  • 3D skin models: Better recapitulation of tissue architecture and cell-cell interactions

  • Consider melanocytes from different donor demographics (age, sex, skin phototype)

• Stimulation parameters optimization:

  • Cyclohexyl salicylate (CHS) concentration range: Typically 100-500 μM

  • Time-course design: Both acute (minutes to hours) and chronic (days) exposure

  • Application method: Direct addition vs. slow-release systems for volatile compounds

• Comprehensive endpoint analysis:

  • Melanogenesis: Spectrophotometric melanin quantification and tyrosinase activity assays

  • Signaling pathways: cAMP levels, Ca²⁺ flux, p38 and p42/44 MAPK phosphorylation

  • Proliferation/differentiation: Cell counting, BrdU incorporation, expression of differentiation markers

  • Morphological changes: Dendricity, cell size, intracellular organization

• Receptor specificity controls:

  • siRNA knockdown of OR2A4/7 to confirm specificity of observed effects

  • Comparison with other olfactory receptors expressed in melanocytes

  • Antagonist studies when available

This systematic approach enables robust investigation of OR2A4/7's role in melanocyte biology, establishing clear causal relationships between receptor activation and observed phenotypic changes.

How can multiplexed immunofluorescence be optimized for studying OR2A4/7 co-localization with other proteins?

Optimizing multiplexed immunofluorescence for OR2A4/7 co-localization studies requires addressing these technical considerations:

• Antibody compatibility planning:

  • Select primary antibodies from different host species (e.g., rabbit anti-OR2A4/7 paired with mouse or goat antibodies against other targets)

  • If same-species antibodies must be used, employ sequential staining with direct labeling of the second primary antibody

  • Validate each antibody individually before combining in multiplex protocols

• Signal optimization strategies:

  • Determine optimal dilution for OR2A7/OR2A4 antibody (typically starting at 1:200-1:1000 for IF)

  • Consider signal amplification systems (tyramide signal amplification) for low-abundance targets

  • Optimize antigen retrieval methods for fixed tissues (test heat-induced vs. enzymatic methods)

• Cross-reactivity prevention:

  • Include careful blocking steps (protein block + serum from secondary antibody host species)

  • Perform extensive washing between sequential staining steps

  • Include single-stained controls to verify specificity of each signal

• Advanced visualization techniques:

  • Employ spectral imaging for separation of overlapping fluorophores

  • Consider super-resolution microscopy techniques for precise co-localization analysis

  • Use appropriate co-localization analysis software and quantitative metrics (Pearson's coefficient, Manders' coefficient)

• Controls and validation:

  • Include negative controls (secondary antibody only)

  • Use positive controls (tissues/cells with known expression patterns)

  • Validate key findings with proximity ligation assays for protein-protein interactions

This methodological approach enables high-quality multiplexed imaging to investigate OR2A4/7 spatial relationships with interacting partners or downstream signaling molecules, providing insights into functional protein networks.

What considerations should guide the interpretation of OR2A4/7 expression in patient-derived samples?

When interpreting OR2A4/7 expression in patient-derived samples, researchers should address these critical considerations:

• Sample quality and preparation variables:

  • Document pre-analytical factors (collection method, time to fixation, fixation duration)

  • Consider tissue heterogeneity and potential sampling bias

  • Normalize for cellularity and tissue composition differences

• Expression quantification standardization:

  • Establish clear scoring systems for immunohistochemistry (H-score, Allred score, etc.)

  • Use digital pathology tools for objective quantification when possible

  • Implement appropriate housekeeping genes/proteins for normalization

• Biological and clinical variables:

  • Stratify analysis by relevant demographic factors (age, sex, ethnicity)

  • Note medication usage and comorbidities that might affect receptor expression

  • Document disease stage, grade, and molecular subtypes

• Comparison across studies:

  • Acknowledge methodological differences between studies (antibody clone, detection system)

  • Consider expression thresholds used to define "positive" versus "negative"

  • Evaluate consistency of findings across independent cohorts

• Clinical correlation rigor:

  • Apply appropriate statistical methods for biomarker association studies

  • Consider multiple testing corrections for exploratory analyses

  • Validate promising associations in independent cohorts

This systematic approach to data interpretation enhances the reliability and clinical relevance of findings related to OR2A4/7 expression in patient samples, supporting potential translation to diagnostic applications.

What emerging technologies might enhance OR2A4/7 research beyond traditional antibody-based methods?

Several cutting-edge technologies offer new avenues for OR2A4/7 research beyond traditional antibody-based approaches:

• CRISPR-based technologies:

  • CRISPR-Cas9 gene editing for precise knockout or knock-in models

  • CRISPRa/CRISPRi for modulating receptor expression without permanent genetic changes

  • CRISPR base editing for introducing specific point mutations to study structure-function relationships

• Advanced imaging techniques:

  • cryo-electron microscopy for structural studies of these challenging GPCRs

  • STORM/PALM super-resolution microscopy for nanoscale localization

  • Lattice light-sheet microscopy for dynamic imaging in living cells with minimal phototoxicity

• Single-cell technologies:

  • Single-cell RNA-seq to resolve heterogeneity in receptor expression

  • Single-cell proteomics to correlate receptor expression with broader proteome changes

  • Spatial transcriptomics to map receptor expression in tissue context

• Biosensor approaches:

  • GPCR-specific biosensors based on FRET/BRET technology

  • Nanobody-based detection systems with potentially improved tissue penetration

  • Development of specific aptamers as alternative affinity reagents

• Computational and AI methods:

  • Structural modeling of these receptors using AlphaFold2 or similar AI platforms

  • Virtual screening for novel ligands targeting OR2A4/7

  • Advanced image analysis algorithms for quantitative histopathology

These emerging technologies may overcome current limitations in studying these challenging receptors, potentially accelerating discoveries about their roles in health and disease.

How can researchers design translational studies to explore OR2A4/7 as therapeutic targets?

To explore the therapeutic potential of OR2A4/7, researchers should consider this translational research framework:

• Target validation:

  • Comprehensive expression profiling across normal and disease tissues

  • Functional studies using genetic manipulation (siRNA, CRISPR) to establish disease relevance

  • Animal models with altered receptor expression to assess systemic effects

• Therapeutic strategy selection:

  • Agonist development for conditions requiring receptor activation (e.g., melanogenesis disorders)

  • Antagonist development for conditions where receptor signaling contributes to pathology

  • Antibody-drug conjugates for targeted delivery to receptor-expressing cells

• Compound screening methodology:

  • High-throughput screening using cAMP or calcium flux assays

  • Structure-based virtual screening informed by computational modeling

  • Fragment-based drug discovery approaches

  • Repurposing screens of approved drugs for novel OR2A4/7 activity

• Efficacy and safety assessment:

  • In vitro evaluation in relevant cell models (melanocytes, cancer cell lines)

  • Ex vivo studies in patient-derived samples

  • In vivo proof-of-concept studies in appropriate animal models

  • Toxicity assessment with particular attention to olfactory function

• Biomarker development:

  • Identify markers of target engagement

  • Develop companion diagnostics to select patients likely to respond

  • Establish pharmacodynamic markers for dose optimization

This comprehensive translational research strategy provides a roadmap for exploring OR2A4/7 as therapeutic targets, addressing both scientific and clinical considerations necessary for developing novel treatments.